Evotec AG of Hamburg, Germany, has sold the core of its single-molecule detection technology and has transferred or licensed the corresponding intellectual property portfolio to Olympus Corp. of Tokyo. This segment of Evotec’s business generated approximately €2.5 million in 2005. Evotec expects up to 5 percent revenue growth from its remaining business and has factored the net financial gains from this deal into its latest report to shareholders.